Dr. Dolsten is the former Chief Scientific Officer and President of Research & Development at Pfizer, where he led global R&D for more than 15 years, overseeing the approval of over 36 medicines and vaccines and advancing more than 150 drug candidates into clinical development. He previously held senior executive roles at Wyeth, Boehringer Ingelheim, and AstraZeneca, with responsibility for global research across multiple therapeutic areas. He currently serves on the boards of Agilent Technologies and Rocket Pharmaceuticals and as Senior Advisor to Blackstone Life Sciences. Dr. Dolsten holds an M.D. and Ph.D. from Lund University, where he is a Visiting Professor, and is a member of The Royal Swedish Academy of Engineering Sciences.